Expression of the PTEN tumor suppressor gene in malignant mammary gland tumors of dogs

American Journal of Veterinary Research

Volumn 67, Issue 1, 2006, Pages 127-133

  Kanae, Yutaka ^a   Endoh, Daiji ^a   Yokota, Hiroshi ^a   Taniyama, Hiroyuki ^a   Hayashi, Masanobu ^a  

^a RAKUNO GAKUEN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL DISEASE; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CONTROLLED STUDY; DOG; EXON; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

AGE FACTORS; ANIMALS; BREAST NEOPLASMS; DNA PRIMERS; DOG DISEASES; DOGS; ELECTROPHORESIS, AGAR GEL; FEMALE; GENE COMPONENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS;

EID: 33645221622     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.1.127     Document Type: Article

References (46)

1. Cohen D, Reif JS, Brodey RS, et al. Epidemiological analysis of the most prevalent sites and types of canine neoplasia observed in a veterinary hospital. Cancer Res 1974;34:2859-2868.
2. Fidler IJ, Brodey RS. The biological behavior of canine mammary neoplasms. J Am Vet Med Assoc 1967;151:1311-1318.
3. Hamilton JM. Comparative aspects of mammary tumors. Adv Cancer Res 1974;19:1-45.
4. Priester WA. Occurrence of mammary neoplasms in bitches in relation to breed, age, tumour type, and geographical region from which reported. J Small Anim Pract 1979;20:1-11.
5. Haas-Kogan D, Shalev N, Wong M, et al. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998; 8:1195-1198.
6. Wang SI, Puc J, Li J, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997;57:4183-4186.
7. Goldberg P, Thor SP, Birck A, et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997;57:3660-3663.
8. Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997; 57:4997-5000.
9. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-3940.
10. Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas ofthe breast. Am J Pathol 1999;155:1253-1260.
11. Rhei E, Kang L, Bogomolniy F, et al. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 1997;57:3657-3659.
12. Koenig A, Bianco SR, Fosmire S, et al. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol 2002;39:458-472.
13. Levine RA, Forest T, Smith C. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Vet Pathol 2002;39:372-378.
14. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-13378.
15. Myers MP, Stolarov JP, Eng C, et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A 1997;94:9052-9057.
16. Khan S, Kumagai T, Vora J, et al. PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer 2004;112:407-410.
17. Li J, Simpson L, Takahashi M, et al. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res 1998;58:5667-5672.
18. Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 1998;95:13513-13518.
19. Ramaswamy S, Nakamura N, Vazquez F, et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1999;96:2110-2115.
20. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.
21. Wu X, Senechal K, Neshat MS, et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1998;95:15587-15591.
22. Huang J, Kontos CD. PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J Biol Chem 2002;277:10760-10766.
23. Wen S, Stolarov J, Myers MP, et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A 2001;98:4622-4627.
24. Gu J, Tamura M, Yamada KM. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol 1998;143:1375-1383.
25. Tamura M, Gu J, Takino T, et al. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res 1999;59:442-449.
26. Tamura M, Gu J, Matsumoto K, et al. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998;280:1614-1617.
27. Weng LP, Smith WM, Dahia PL, et al. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res 1999;59:5808-5814.
28. Garcia JM, Silva J, Pena C, et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 2004;41:117-124.
29. Khan S, Kumagai T, Vora J, et al. PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer 2004;112:407-410.
30. Lee CH, Kim WH, Lim JH, et al. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors. J Vet Sci 2004;5:63-69.
31. Nieto A, Pena L, Perez-Alenza MD, et al. Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: clinical and pathologic associations and prognostic significance. Vet Pathol 2000;37:239-247.
32. Brunetti B, Sarli G, Preziosi R, et al. E-cadherin expression in canine mammary carcinomas with regional lymph node metastases. J Vet Med A Physiol Pathol Clin Med 2003;50:496-500.
33. Misdorp W, Cotchin E, Hampe JF, et al. Canine malignant mammary tumors. 3. Special types of carcinomas, malignant mixed tumors. Vet Pathol 1973;10:241-256.
34. Misdorp W, Cotchin E, Hampe JF, et al. Canine malignant mammary tumours. I. Sarcomas. Vet Pathol 1971;8:99-117.
35. Misdorp W. Canine malignant mammary tumors. 2. Adenocarcinomas, solid carcinomas and spindle cell carcinomas. Vet Pathol 1972;9:447-470.
36. Celi FS, Zenilman ME, Shuldiner AR. A rapid and versatile method to synthesize internal standards for competitive PCR. Nucleic Acids Res 1993;21:1047.
37. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15:356-362.
38. Teng DH, Hu R, Lin H, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997; 57:5221-5225.
39. Sharrard RM, Maitland NJ. Alternative splicing of the human PTEN/MMAC1/TEP1 gene. Biochim Biophys Acta 2000;1494:282-285.
40. Huang DH. SpliceInfo: an information repository for mRNA alternative splicing in human genome. Nucleic Acids Res 2005; 33:D80-D85.
41. Michalickova K, Susie M, Willing MC, et al. Mutations of the alpha2(V) chain of type V collagen impair matrix assembly and produce Ehlers-Danlos syndrome type I. Hum Mol Genet 1998;7:249-255.
42. Schwarze U, Goldstein JA, Byers pH. Splicing defects in the COL3A1 gene: marked preference for 5′ (donor) spice-site mutations in patients with exon-skipping mutations and Ehlers-Danlos syndrome type IV. Am J Hum Genet 1997;61:1276-1286.
43. Georgescu MM, Kirsch KH, Akagi T, et al. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci U S A 1999;96:10182-10187.
44. Lee JO, Yang H, Georgescu MM, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999;99:323-334.
45. Ueda K, Nishijima M, Inui H, et al. Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers. Jpn J Cancer Res 1998;89:17-21.
46. Gilliland G, Perrin S, Blanchard K, et al. Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction. Proc Natl Acad Sci U S A 1990; 87:2725-2729.